ADMA Biologics is a biopharmaceutical and immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases. The company's marketed products consist of: Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen; and Bivigam, which is indicated for the treatment of primary humoral immunodeficiency. The company is also developing a pipeline of plasma-derived therapeutics, including its key pipeline product candidate, RI-002, for the treatment of Primary Immune Deficiency Disease.

Beacon Roofing Supply is a distributor of roofing materials and complementary building products in the United States and Canada. The complementary building products the company distributes include siding, windows, insulation, waterproofing systems, wallboard, acoustical ceilings, and other exterior and interior building products. The company purchases products from manufacturers and then distributes these goods to a customer base consisting of contractors, and to a lesser extent, home builders, retailers, and other building materials suppliers. The company supports its customers with services such as advice and assistance on product identification, specification and technical support, and training services.

Compass Diversified Holdings is a statutory trust that acquires and manages a group of small and middle-market businesses. The company's businesses include: branded consumer businesses, which includes its subsidiary, 5.11 ABR Corp., that provides purpose-built tactical apparel and gear for law enforcement, firefighters, EMS, and military special operations as well as outdoor and adventure enthusiasts; and niche industrial businesses, which includes its subsidiary, Foam Fabricators Inc., that designs and manufactures custom molded protective foam solutions and original equipment manufacturer components made from expanded polystyrene and other expanded polymers.

Digital Turbine, through its subsidiaries, delivers end-to-end platform solution for mobile operators, application developers, device original equipment manufacturers (OEMs), and other third parties. The company's advertising business is comprised of Operator and OEM, an advertiser solution for carrier and OEM inventory comprised of services including Ignite?, a software platform with targeted media delivery and management capabilities; and Other recurring and lifecycle products, features, and services delivered on the Ignite platform. The company has launched Ignite with mobile operators and OEMs in North America, Latin America, Europe, Asia Pacific, India and Israel.

Energy Transfer is a holding company. Through its subsidiaries, the company is engaged in natural gas operations, including natural gas midstream and intrastate transportation and storage and interstate natural gas transportation and storage, and crude oil, natural gas liquid (NGL) and refined products transportation, terminalling services and acquisition and marketing activities. In addition, the company owns investments in other businesses. The company's segments include: intrastate transportation and storage; interstate transportation and storage; midstream; NGL and refined products transportation and services; crude oil transportation and services; investment in Sunoco LP; investment in USAC; and all other.

JMP Group is a holding company. Through its subsidiaries, the company is a capital markets firm. The company provides investment banking, sales and trading, and equity research services to corporate and institutional clients as well as alternative asset management products and services to institutional investors and individuals. In addition, the company manages and invests in corporate credit instruments through collateralized loan obligations and direct investments, and it serves as the investment advisor to a business development company. The company's investment banking provides capital raising services, mergers and acquisitions transaction services, and other advisory services to corporate clients.

Kimball International creates furnishings. The company's furniture solutions are used in collaborative and open work spaces, conference and meeting/huddle rooms, training rooms, private offices, learning areas, classrooms, lobby/reception areas, and dining/cafe areas with a mix of wood, metal, laminate, paint, fabric, solid surface, and plastic options. In addition, the company provides products designed for the healthcare market, such as casegoods and seating for patient exam rooms and lounge areas. In the hospitality industry, the company's products include headboards, tables, seating, vanities, casegoods, lighting, and products with technology features.

Kodiak Sciences is a clinical stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. The company's main product candidate is KSI-301, a biologic therapy built with the company's antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301 is used to treat patients with wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and macular edema due to retinal vein occlusion. The company has applied its antibody biopolymer conjugate platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate.

Lumos Pharma is a clinical-stage immuno-oncology company develops immunotherapeutic products for the treatment of patients with cancer. The company's small-molecule product candidates in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway, which is a pathway for cancer immune escape. These product candidates, indoximod and NLG802 (a prodrug of indoximod), are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer. The company's small molecule product candidate, NLG207, which is a nanoparticle-drug conjugate, consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor.

Old Second Bancorp is a bank holding company. Through its subsidiaries, the company conducts community banking and trust business. The company is a banking business providing a range of deposit products, trust and wealth management services, and lending services; commercial, industrial, consumer and real estate lending, safe deposit operations, and additional services for individual customers. The company's lending activities include making commercial and consumer loans, mainly on a secured basis. The company provides various wealth management, investment, agency, and custodial services for individual, corporate, and not-for-profit clients. The company also originates residential mortgages, providing a range of mortgage products.

Organogenesis Holdings is a regenerative medicine company focused on the development, manufacture and commercialization of solutions. The company's Advanced Wound Care products include Apligraf for the treatment of VLUs and DFUs; Dermagraft for the treatment of DFUs; PuraPly Antimicrobial (PuraPly AM) to address biofilm across various wound types; and Affinity and NuShield to address various wound sizes and types. The company's Surgical and Sports Medicine products include ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical application in targeted soft tissue repairs; and PuraPly AM for surgical treatment of open wounds.

Parsons is a provider of technology-driven solutions in the defense, intelligence and critical infrastructure markets. The company provides technical design and engineering services and software to address the company's customers' challenges. The company has developed significant expertise and differentiated capabilities in key areas of cybersecurity, intelligence, defense, military training, connected communities, physical infrastructure and mobility solutions. The company performs work in various foreign countries through local subsidiaries, joint ventures and foreign offices maintained to carry out specific projects.

Savara is an orphan lung disease company. The company's drug development pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor in development for pulmonary alveolar proteinosis and in development for nontuberculous mycobacterial lung infection; and AeroVanc, an inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.